Product Information
TEMAZEPAM 22.5 MG CAPSULE is a generic product labeled by Alembic Pharmaceuticals Inc., priced at $1.5492 per EA under NDC 62332038130. Its NADAC has been published 375 times since Jul 31, 2019.
FDA first approved this application on Nov 23, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
22.5 mg/1
Manufacturer
Alembic Pharmaceuticals Inc.NDC
62332038130
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TEMAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA211542FDA Approved
11/23/2018
TE Code
AB
On Market Since
11/27/2018
Pharmacological Classes
Price Statistics
The NADAC for TEMAZEPAM 22.5 MG CAPSULE has been published 375 times since Jul 31, 2019, and over the history we have for it it has declined 58.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.5492 per EA |
|---|---|
| All-time high | $3.7033 (Aug 14, 2019) |
| All-time low | $1.1572 (Nov 20, 2024) |
| 52-week high | $2.0272 |
| 52-week low | $1.5147 |
| Median price | $2.1355 |
| Average price | $2.2568 |
| Largest weekly change | +81.6% (Mar 23, 2022) |
| Weeks tracked | 375 |
| Tracking since | Jul 31, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Temazepam market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alembic Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Temazepam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TEMAZEPAM 22.5 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for TEMAZEPAM 22.5 MG CAPSULE, manufactured by Alembic Pharmaceuticals Inc., is $1.5492 per EA (NDC 62332038130), effective Sep 30, 2026.
How has the price of TEMAZEPAM 22.5 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for TEMAZEPAM 22.5 MG CAPSULE has declined 58.2%. It has been tracked across 375 weekly CMS publications since Jul 31, 2019.
What are the highest and lowest recorded NADAC prices for TEMAZEPAM 22.5 MG CAPSULE?
Since Jul 31, 2019, the NADAC for TEMAZEPAM 22.5 MG CAPSULE has ranged from a low of $1.1572 (Nov 20, 2024) to a high of $3.7033 (Aug 14, 2019), with a median of $2.1355 per EA.
Are there cheaper alternatives to TEMAZEPAM 22.5 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of TEMAZEPAM 22.5 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TEMAZEPAM 22.5 MG CAPSULE?
TEMAZEPAM 22.5 MG CAPSULE (NDC 62332038130) is labeled by Alembic Pharmaceuticals Inc., and CMS classifies it as a generic product.